Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62015TN0214

    Case T-214/15: Action brought on 23 April 2015 — Novartis v OHIM — Meda (Zymara)

    OJ C 205, 22.6.2015, p. 40–40 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    22.6.2015   

    EN

    Official Journal of the European Union

    C 205/40


    Action brought on 23 April 2015 — Novartis v OHIM — Meda (Zymara)

    (Case T-214/15)

    (2015/C 205/53)

    Language in which the application was lodged: English

    Parties

    Applicant: Novartis AG (Basel, Switzerland) (represented by: M. Douglas, lawyer)

    Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)

    Other party to the proceedings before the Board of Appeal: Meda AB (Solna, Sweden)

    Details of the proceedings before OHIM

    Applicant: Other party to the proceedings before the Board of Appeal

    Trade mark at issue: Community word mark ‘Zymara’ — Application for registration No 9 982 745

    Procedure before OHIM: Opposition proceedings

    Contested decision: Decision of the Fifth Board of Appeal of OHIM of 6 February 2015 in Case R 550/2014-5

    Form of order sought

    The applicant claims that the Court should:

    Annul the contested decision;

    Order OHIM to pay the costs.

    Pleas in law

    The Board of Appeal has misinterpreted the goods which are ‘pharmaceutical preparations, namely preparations for the treatment of cancer’;

    The Board of Appeal has incorrectly based its decision on spelling rules which are not existing;

    The Board of Appeal has ignored arguments put forward with respect to the comparison of signs and, therefore, incorrectly held that the signs are phonetically similar only to a low degree;

    The Board of Appeal has put too much wait on the word beginnings within the visual comparison.


    Top